WuXi AppTec : INSIDE INFORMATION PROPOSED DISPOSAL OF A SHARES BY A SHAREHOLDER
September 11, 2020 at 07:55 am EDT
Share
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)
INSIDE INFORMATION
PROPOSED DISPOSAL OF A SHARES BY A SHAREHOLDER
This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有 限公司) (the "Company") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).
Reference is made to the announcement of the Company dated April 30, 2019 in relation to, among other things, the end of lock-up period of the Restricted A Shares under the A Share IPO (the "Announcement"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.
- 1 -
PROPOSED DISPOSAL OF A SHARES BY A SHAREHOLDER
The Company has been informed by the following shareholder of the Company (the "Selling Shareholder") that it intends to dispose of certain A Shares (the "Proposed Disposal") during the period as stipulated below through block trading, which shall be subject to percentage restrictions under the applicable laws of the People's Republic of China. The details of the Proposed Disposal are set out below.
Maximum
Maximum
percentage of
number of
total issued
A Shares to
shares of the
be disposed
Company
Price range
of by the
under the
for the
Reason for
Selling
Selling
Proposed
Method of the
Period of the Proposed
Proposed
Source of A Shares for the
the Proposed
Shareholder
Shareholder
Disposal
Proposed Disposal
Disposal
Disposal
Proposed Disposal
Disposal
HCFII WX (HK)
Up to
Up to 1%
By block trading:
Block trading:
Based on
From other means
Normal
Holdings Limited
23,788,846
up to 23,788,846
September 17, 2020 to
market price
(including A Shares
divestment of
A Shares
A Shares
December 15, 2020
obtained before the A Share
fund
IPO and pursuant to the
capitalization of reserve of
the Company in 2018 and
2019)
The Selling Shareholder will decide whether to carry out the Proposed Disposal after taking into account various factors, including market conditions and share price of the Company. Accordingly, the number of the A Shares to be disposed of by the Selling Shareholder under the Proposed Disposal are subject to change. The Proposed Disposal will not lead to any change of control in the Company.
Shareholders and potential investors should exercise caution when dealing in the securities of the Company.
By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman
Hong Kong, September 11, 2020
As of the date of this announcement, the board of directors of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive directors.
*For identification purpose only
- 2 -
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
WuXi AppTec Co. Ltd. published this content on 11 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 September 2020 11:54:01 UTC
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:
- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;
- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;
- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;
- other (0.1%).
Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .